Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. CDN Services

We are analyzing https://link.springer.com/protocol/10.1007/978-1-61779-188-8_8.

Title:
Antibody Targeted siRNA Delivery | SpringerLink
Description:
It is very clear that RNA interference (RNAi) is a potent and versatile tool for gene silencing. One of the hurdles to making siRNA/miRNA a human therapeutic includes effective in vivo delivery and being able to deliver drugs to target cells only. The commercial...
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {πŸ“š}

  • Science
  • Education
  • Telecommunications

Content Management System {πŸ“}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {πŸ“ˆ}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {πŸ’Έ}

We can't see how the site brings in money.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {πŸ”}

article, pubmed, google, scholar, cas, delivery, sirna, protocol, rna, privacy, cookies, content, information, publish, therapeutic, antibody, gene, cells, nature, usa, search, toloue, interference, silencing, vivo, sirnas, access, download, springer, usd, personal, data, log, journal, research, oligonucleotides, targeted, masoud, ford, book, methods, rnai, agents, specific, small, interfering, chapter, nat, biotechnol, author,

Topics {βœ’οΈ}

month download article/chapter antibody-based delivery agents developed antibody-based agents small interfering rnas small interfering rna targeted mrna degradation privacy choices/manage cookies device instant download making sirna/mirna therapeutic oligonucleotides editor information editors receptor-targeted sirnas humana press journal finder publish rna carrier proteins double-stranded rna worcester state college european economic area cell surface receptors current transport systems sterically stabilized liposomes lymphatic vessel growth cell-surface receptors protocol usdΒ 49 selective gene silencing conditions privacy policy specific cell types specific genetic interference animal disease models silencing viral infection accepting optional cookies protocol cite integrin lymphocyte function cultured mammalian cells receptor-mediated endocytosis main content log online author correspondence protocol toloue therapeutic silencing gene delivery deliver sirna antibody mediated check access ethics access journal publish rna interference social media permissions reprints antibody complexes

Schema {πŸ—ΊοΈ}

ScholarlyArticle:
      headline:Antibody Targeted siRNA Delivery
      pageEnd:139
      pageStart:123
      image:https://media.springernature.com/w153/springer-static/cover/book/978-1-61779-188-8.jpg
      genre:
         Springer Protocols
      isPartOf:
         name:Therapeutic Oligonucleotides
         isbn:
            978-1-61779-188-8
            978-1-61779-187-1
         type:Book
      publisher:
         name:Humana Press
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Masoud M. Toloue
            affiliation:
                  name:Bioo Scientific Corporation
                  address:
                     name:Bioo Scientific Corporation, Austin, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Lance P. Ford
            affiliation:
                  name:Bioo Scientific Corporation
                  address:
                     name:Bioo Scientific Corporation, Austin, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      keywords:siRNA, miRNA delivery, antibody directed delivery, conjugation kit, therapeutic monoclonal antibodies, receptor-mediated endocytosis, in vivo models, therapeutic small RNA
      description:It is very clear that RNA interference (RNAi) is a potent and versatile tool for gene silencing. One of the hurdles to making siRNA/miRNA a human therapeutic includes effective in vivo delivery and being able to deliver drugs to target cells only. The commercial success of in vivo applications of RNAi hinges on the development of new delivery methods. Our strategy involves the use of antibody-based delivery agents to target and deliver siRNA into specific cell types. We have developed antibody-based agents for directed delivery into cultured cells and animal disease models. Using antibodies against various cell surface receptors, modified siRNAs are attached to antibody complexes using RNA carrier proteins. The complex can then be intravenously administered to in vivo models and taken up by specific cells via receptor-mediated endocytosis. The labile structure of the linking agents enables release of siRNA molecules post internalization. Using this targeting strategy, we have developed a method that allows any commercially available or recombinant antibody to be conjugated to siRNA for delivery purposes.
      datePublished:2011
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
      context:https://schema.org
Book:
      name:Therapeutic Oligonucleotides
      isbn:
         978-1-61779-188-8
         978-1-61779-187-1
Organization:
      name:Humana Press
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Bioo Scientific Corporation
      address:
         name:Bioo Scientific Corporation, Austin, USA
         type:PostalAddress
      name:Bioo Scientific Corporation
      address:
         name:Bioo Scientific Corporation, Austin, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Masoud M. Toloue
      affiliation:
            name:Bioo Scientific Corporation
            address:
               name:Bioo Scientific Corporation, Austin, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Lance P. Ford
      affiliation:
            name:Bioo Scientific Corporation
            address:
               name:Bioo Scientific Corporation, Austin, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Bioo Scientific Corporation, Austin, USA
      name:Bioo Scientific Corporation, Austin, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {πŸ”—}(69)

Analytics and Tracking {πŸ“Š}

  • Google Tag Manager

Libraries {πŸ“š}

  • Clipboard.js

CDN Services {πŸ“¦}

  • Pbgrd

3.89s.